Business context and reporting period
Ekso Bionics Holdings, Inc. (the registrant named in the filing; not Chronoscale Holdings Corp.) filed this unaudited Form 10-Q for the quarter ended September 30, 2015. It develops and sells wearable exoskeletons, with medical devices and engineering services as its two reportable segments. Unless otherwise noted, amounts below are in thousands of dollars.
Financial performance and position
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Revenue | $2,915 | $1,588 | $6,718 | $3,847 |
| Gross profit | $468 | $480 | $1,373 | $1,005 |
| Gross margin | 16.1% | 30.2% | 20.4% | 26.1% |
| Operating loss | $(5,181) | $(3,732) | $(14,909) | $(11,935) |
| Net income (loss) | $(5,185) | $12,024 | $(14,945) | $(13,614) |
| Operating cash flow | Not stated quarterly | Not stated quarterly | $(13,082) | $(12,296) |
- Q3 revenue rose 84% year over year; nine-month revenue increased 75%. Medical-device revenue grew 39% in Q3 and 56% year to date; engineering-services revenue grew 128% and 95%, respectively.
- Revenue growth did not translate into higher Q3 gross profit: medical-device service, field-correction and technology-improvement costs weighed on margins. Management expected elevated costs for the next quarter or two. Engineering-services gross profit improved, supported by a better mix of higher-margin projects.
- Operating expenses increased 34% in Q3 and 26% for the first nine months, driven mainly by sales and marketing and R&D investment. Nine-month net loss widened by $1,331.
- Q3 2014 net income included a $15,773 non-cash gain on warrant liability. The warrants were amended in November 2014 and are no longer recorded as liabilities; the prior-quarter gain makes the net-income comparison misleading.
- Cash was $11,238 at September 30, 2015, versus $25,190 at December 31, 2014. Nine-month investing cash outflow was $962, and financing provided $92. Working capital was $8,992, based on current assets of $17,248 less current liabilities of $8,256.
- Total liabilities were $12,880; capital lease obligations were $244, including $79 current. The filing reports no material conventional debt balance beyond these obligations.
Changes, outlook, and risks
- Management cited average monthly net cash use of approximately $1.6 million and believed available resources would meet obligations into the second quarter of 2016, based on assumptions including revenue and gross-profit growth. It said additional financing would be required and planned to seek it through collaborations, equity, debt or warrant exercises within two to four quarters. Availability and terms were not assured; equity financing could dilute shareholders.
- The company was developing a home-use medical exoskeleton and industrial models, including a passive, unpowered product with prototypes undergoing field testing. These were development and commercialization plans, not firm financial guidance.
- The FDA had accepted the Ekso device’s 510(k) submission for substantive review but requested additional information in September 2015. Management considered a 2016 decision more likely than a 2015 decision; clearance was uncertain. Continued marketing under the existing Class I listing could be challenged, potentially leading to a sales suspension, recall or penalties.
- An FDA inspection resulted in a Form 483 with four observations concerning informed consent, adverse-event reporting and records maintenance. The company submitted a response describing corrective and preventive actions. The observations were not a final determination of non-compliance.
- Since July 1, 2015, seven reportable Ekso GT device events had been identified; the filing stated there were no reported patient injuries. The company reported a voluntary field correction, accelerated maintenance, and manufacturing and component changes.
- Disclosure controls and procedures were concluded to be ineffective as of September 30, 2015. Management said previously identified control deficiencies had been addressed, but the controls had not operated long enough to be tested for effectiveness over time.
- Customer concentration was notable: one customer accounted for 48% of Q3 2015 sales and 33% of nine-month sales. The company also disclosed foreign-currency exposure without hedging and annual minimum royalties of $50 under patent licenses.
Important facts for investors to verify
- Confirm the registrant identity: the supplied filing is for Ekso Bionics Holdings, Inc., not Chronoscale Holdings Corp.
- Track cash burn, liquidity and whether new financing is secured before the stated runway into Q2 2016 expires.
- Monitor FDA review, the response to its information request, any clearance restrictions, and resolution of the Form 483 observations and device-event follow-up.
- Assess whether medical-device service and field-correction costs subside and whether revenue growth produces sustained gross-margin improvement.
- Evaluate customer concentration, planned spending, potential shareholder dilution, and progress in remediating ineffective disclosure controls.